Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,063 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective inhibition of nuclear factor-κB by nuclear factor-κB essential modulator-binding domain peptide suppresses the metastasis of highly metastatic oral squamous cell carcinoma.
Tanaka T, Nakayama H, Yoshitake Y, Irie A, Nagata M, Kawahara K, Takamune Y, Yoshida R, Nakagawa Y, Ogi H, Shinriki S, Ota K, Hiraki A, Ikebe T, Nishimura Y, Shinohara M. Tanaka T, et al. Among authors: nakagawa y. Cancer Sci. 2012 Mar;103(3):455-63. doi: 10.1111/j.1349-7006.2011.02174.x. Epub 2012 Jan 16. Cancer Sci. 2012. PMID: 22136381 Free PMC article.
A low Dicer expression is associated with resistance to 5-FU-based chemoradiotherapy and a shorter overall survival in patients with oral squamous cell carcinoma.
Kawahara K, Nakayama H, Nagata M, Yoshida R, Hirosue A, Tanaka T, Nakagawa Y, Matsuoka Y, Kojima T, Takamune Y, Yoshitake Y, Hiraki A, Shinohara M. Kawahara K, et al. Among authors: nakagawa y. J Oral Pathol Med. 2014 May;43(5):350-6. doi: 10.1111/jop.12140. Epub 2013 Dec 10. J Oral Pathol Med. 2014. PMID: 24325353
Osteopontin-integrin α(v)β(3) axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma.
Nakamura T, Shinriki S, Jono H, Ueda M, Nagata M, Guo J, Hayashi M, Yoshida R, Ota T, Ota K, Kawahara K, Nakagawa Y, Yamashita S, Nakayama H, Hiraki A, Shinohara M, Ando Y. Nakamura T, et al. Among authors: nakagawa y. FEBS Lett. 2015 Jan 16;589(2):231-9. doi: 10.1016/j.febslet.2014.12.004. Epub 2014 Dec 10. FEBS Lett. 2015. PMID: 25497015 Free article.
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y, Yoshida R, Hirosue A, Ogi H, Hiraki A, Jono H, Hamada A, Yoshida K, Nishimura Y, Nakamura Y, Shinohara M. Yoshitake Y, et al. Among authors: nakagawa y. Clin Cancer Res. 2015 Jan 15;21(2):312-21. doi: 10.1158/1078-0432.CCR-14-0202. Epub 2014 Nov 12. Clin Cancer Res. 2015. PMID: 25391695 Clinical Trial.
[Relationship of Prescribed Drugs with the Risk of Fall in Inpatients].
Kozono A, Isami K, Shiota K, Tsumagari K, Nagano M, Inoue D, Adachi R, Hiraki Y, Nakagawa Y, Kamimura H, Yamamichi K. Kozono A, et al. Among authors: nakagawa y. Yakugaku Zasshi. 2016;136(5):769-76. doi: 10.1248/yakushi.15-00245. Yakugaku Zasshi. 2016. PMID: 27150933 Free article. Japanese.
Prognostic utility and cutoff differences of NT-proBNP level across subgroups in heart failure with preserved ejection fraction: Insights from the PURSUIT-HFpEF Registry.
Sakamoto D, Sotomi Y, Matsuoka Y, Nakatani D, Okada K, Sunaga A, Kida H, Sato T, Kitamura T, Seo M, Yano M, Hayashi T, Nakagawa A, Nakagawa Y, Tamaki S, Yasumura Y, Yamada T, Hikoso S, Sakata Y; OCVC-Heart Failure Investigator. Sakamoto D, et al. Among authors: nakagawa y. J Card Fail. 2024 Nov 16:S1071-9164(24)00925-4. doi: 10.1016/j.cardfail.2024.10.440. Online ahead of print. J Card Fail. 2024. PMID: 39557334
4,063 results